小细胞肺癌患者来源异种移植模型的基因组与功能保真性
该研究采用组织采集流程与自动化微流控CTC富集平台,在2年内以89%和38%的效率分别建立17例活检来源和17例CTC来源的SCLC PDX模型。全外显子测序显示体细胞变异在患者肿瘤与PDX间稳定保持,早期传代PDX维持 founder PDX的基因组和转录谱。30个PDX模型的体内EP治疗显示初治患者PDX更敏感,耐药与MYC基因特征表达升高相关。
要点
- 体细胞变异在患者肿瘤与PDX间稳定保持,早期传代维持基因组与转录谱
- EP初治患者PDX对EP更敏感,耐药对应MYC基因特征表达升高
核心结论
- SCLC PDX模型可从活检和CTC高效建立,并保持患者肿瘤的基因组和功能特征。
研究设计与样本
- 研究采用既定临床转化流程采集组织,并用自动化微流控平台富集CTC。
- 2年内建立17例活检来源PDX和17例CTC来源PDX,效率分别为89%和38%。
- 对30个PDX模型进行体内依托泊苷联合铂(EP)治疗。
主要发现
- 全外显子测序显示体细胞变异在患者肿瘤与PDX间稳定保持。
- 早期传代PDX维持 founder PDX的基因组和转录谱。
- 30个PDX模型中,EP初治患者来源PDX对EP敏感性更高。
- EP耐药与MYC基因特征表达升高相关。
- 来自同一患者多时间点的连续CTC来源PDX准确重现了该患者疾病的 evolving 药物敏感性。
临床怎么用
- 可利用活检或CTC建立SCLC PDX模型以支持转化研究。
- PDX模型可用于评估EP敏感性及探索MYC相关耐药机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Small cell lung cancer (SCLC) patient-derived xenografts (PDX) can be generated from biopsies or circulating tumor cells (CTC), though scarcity of tissue and low efficiency of tumor growth have previously limited these approaches. Applying an established clinical-translational pipeline for tissue collection and an automated microfluidic platform for CTC enrichment, we generated 17 biopsy-derived PDXs and 17 CTC-derived PDXs in a 2-year timeframe, at 89% and 38% efficiency, respectively. Whole-exome sequencing showed that somatic alterations are stably maintained between patient tumors and PDXs. Early-passage PDXs maintain the genomic and transcriptional profiles of the founder PDX. In vivo treatment with etoposide and platinum (EP) in 30 PDX models demonstrated greater sensitivity in PDXs from EP-naïve patients, and resistance to EP corresponded to increased expression of a MYC gene signature. Finally, serial CTC-derived PDXs generated from an individual patient at multiple time points accurately recapitulated the evolving drug sensitivities of that patient's disease. Collectively, this work highlights the translational potential of this strategy.Significance: Effective translational research utilizing SCLC PDX models requires both efficient generation of models from patients and fidelity of those models in representing patient tumor characteristics. We present approaches for efficient generation of PDXs from both biopsies and CTCs, and demonstrate that these models capture the mutational landscape and functional features of the donor tumors. Cancer Discov; 8(5); 600-15. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 517.
引用
- Drapkin BJ, George J, Christensen CL, et al. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov. 2018. PMID: 29483136. doi:10.1158/2159-8290.CD-17-0935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。